(Bloomberg) — Mylan NV’s chief executive officer faced skeptical lawmakers Wednesday as the House’s Oversight Committee questioned the drugmaker’s honesty, ethics and executive pay during a hearing examining how the company raised prices on its EpiPen allergy shot.
In several heated back-and-forths with CEO Heather Bresch, Committee Chairman Jason Chaffetz, a Utah Republican, accused Bresch and Mylan of downplaying its profits while at the same time paying its senior executives hundreds of millions of dollars. Bresch was testifying about the pens’ sharp price increases, which have become the latest high-profile example of rising drug costs.
Chaffetz told a packed hearing room in Washington that he found Mylan’s arguments that it makes only about $50 of profit on each pen “a little hard to believe.” He was followed by Maryland Rep. Elijah Cummings, the panel’s top Democrat, who accused the drugmaker of taking advantage of the U.S. health care system.
Mylan raised EpiPen’s “to get filthy rich at the expense of our constituents,” Cummings said. Their strategy was to “find an old cheap drug that has virtually no competition and raise the price over and over and over again as high as you can.”
Bresch’s compensation was an issue for lawmakers as well, as it often is when CEOs appear before lawmakers. When asked about her pay, Bresch briefly stuttered before saying, “It’s in the middle” compared to others in the industry. Bresch was awarded $19.4 million in pay last year, which made her the 25th-best paid executive in the health care industry, according to data compiled by Bloomberg. Her response generated more outrage from lawmakers.
“I am a very pro-business Republican, yet I am really sickened by what I’ve heard about this situation,” said Rep. John Duncan of Tennessee. “Nobody can really earn or deserve $19 million a year.”
Mansions and jets
Cummings predicted that despite all the questioning, little would change.
“Today, we will hold yet another hearing where the industry will take these punches, but then go right ahead and keep raising their prices,” Cummings said. “They will fly back to their mansions in their private jets and laugh all the way to the bank while our constituents suffer, file for bankruptcy, and watch their children get sicker, and in some cases die.”
Bresch, who is the daughter of Democratic Senator Joe Manchin, of West Virginia, made her case to lawmakers that Congress should recognize that Mylan has increased access to the drug. She said in her prepared testimony that Mylan only takes home about $100 after rebates, fees and discounts for each two-pack of the shots.
Bresch said that Mylan wasn’t getting every dollar of the price increases. “Recent Epipen price increases have not yielded the revenue to Mylan that many people assume,” she told the committee.
“Looking back, I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients” who had to pay the full list price or more, she said. “We never intended this.”
“You never anticipated this? You raised the price, what did you think was going to happen?” Chaffetz asked her.
The company, which is run from Canonsburg, Pennsylvania, but is officially registered in the Netherlands after a so-called tax inversion, is facing a multiple inquiries from lawmakers and law enforcement. The probes include state attorneys general investigating possible Medicaid fraud as well as legislative committees demanding internal documents from the company about EpiPen’s price.